Connect Biopharma Surges 17.45% as Rademikibart Nears Key Phase 3 Data Readouts in Inflammatory Diseases

Connect Biopharma surges 17.45% in pre-market trading on Nov 18, 2025, signaling strong investor confidence ahead of key developments. The biotech firm’s shares jumped on speculation around its late-stage pipeline and strategic positioning in inflammatory disease treatments.

The rally follows renewed focus on Connect’s lead candidate rademikibart, an IL-4 receptor alpha-targeting antibody in Phase 3 trials for atopic dermatitis and asthma. Analysts highlight the asset’s potential to address unmet needs in dermatology and respiratory markets, with upcoming data readouts likely to drive momentum.

Founded in 2012, the San Diego-based company has maintained a disciplined R&D approach, focusing on high-impact inflammatory disease targets. Recent trading activity reflects positioning ahead of potential regulatory milestones, with investors parsing risk-reward dynamics in biotech’s volatile therapeutic landscape.

Technical indicators suggest continuation of upward momentum, with the 200-day moving average acting as a key support level. Volume profiles confirm conviction in the move, though short-term volatility remains a factor given the sector’s sensitivity to clinical data releases.

A hypothetical backtest strategy could involve entering a long position pre-earnings events with a stop-loss at 10% below entry. Historical patterns show pre-market spikes often consolidate during regular hours, suggesting a trailing stop approach to capture trend continuation while managing downside risk. This aligns with the current setup as the stock tests key resistance levels ahead of its next major catalyst.